J Endovasc Ther:对TAAA患者使用多层流动调制器进行腔内修复是安全和有效的(STRATO试验)

2016-06-29 Mechront 译 MedSci原创

STRATO试验数据显示,对于不适合开放手术或开窗覆膜支架的胸腹主动脉瘤患者,分支血管通畅和稳定动脉瘤血栓形成的证据表明,使用多层流动调制器进行腔内修复,在3年的时间内是安全和有效的。这项前瞻性、多中心、随机试验包括23例(平均年龄76岁;19为男性)Crawford II和III型胸腹主动脉瘤(TAAA)患者。平均TAAA直径为6.5厘米,平均长度为162.5毫米。所有患者使用第一代多层流调制器

STRATO试验数据显示,对于不适合开放手术或开窗覆膜支架的胸腹主动脉瘤患者,分支血管通畅和稳定动脉瘤血栓形成的证据表明,使用多层流动调制器进行腔内修复,在3年的时间内是安全和有效的。

这项前瞻性、多中心、随机试验包括23例(平均年龄76岁;19为男性)Crawford II和III型胸腹主动脉瘤(TAAA)患者。平均TAAA直径为6.5厘米,平均长度为162.5毫米。

所有患者使用第一代多层流调制器(Cardiatis)进行腔内修复。患者出院前需要进行体格检查,对分支血管通畅性进行影像学评估。在1、3(可选)、6、12、24和36个月时进行体格检查和CT或MRI随访。研究的主要结果是全因死亡率和与分支血管通畅相关的稳定动脉瘤血栓形成。

结果显示,院内或术后30天内没有死亡发生,但是随访期间有7名患者死亡。1例发生在随访第1年,2例发生在随访第2年,4例发生在随访第3年。无死亡病例被确定为与动脉瘤有关。

研究人员报告说,研究期间没有出现脊髓损伤、动脉瘤破裂、移动设备移位/骨折、或呼吸系统/肾或外周并发症。在随访1年中,有6例患者少有一个严重不良事件报告,包括1例围手术期卒中、1例需要手术修复的血管并发症、1例动脉瘤扩张需要再次手术、1例设备移位、1例血肿和1例闭塞。在后续的随访中分别有2例和3例患者需要移除设备和设备丢失。只有11例患者的设备持续存在3年。

在整个队列中,20例患者中有15例在1年内维持稳定的动脉瘤血栓形成;13例患者中有12例在2年内维持稳定的动脉瘤血栓形成;11例患者中有10例在3年内维持稳定的动脉瘤血栓形成。根据研究结果,1年,2年和3年的分支血管通畅率分别为96%、100%和97%。

研究期间发生内漏九例;9名患者进行了十一例再处理(3例手术)。

20例患者中有18例在1年内维持最大动脉瘤直径的稳定性,2年内和3年内的数据分别为11/13和9/11。

10例患者有可供分析的CT数据。数据显示,第3年,动脉瘤流量与总流量相比,下降83%;平均血栓体积与总体积相比则增加159%。

研究结果表明,对TAAA患者使用多层流动调制器进行腔内修复是安全和有效的。

原始出处:

Vaislic CD, et al. J Endovasc Ther. 2016;doi:10.1177/1526602816653095.

Endovascular aneurysm repair with multilayer flow modulator safe, effective at 3 years
.Healio.June 28, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656708, encodeId=96ea1656e0876, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Aug 20 16:04:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995745, encodeId=31561995e450d, content=<a href='/topic/show?id=edd21655a4' target=_blank style='color:#2F92EE;'>#AAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1655, encryptionId=edd21655a4, topicName=AAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Dec 14 08:04:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938602, encodeId=5da719386024d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jul 30 06:04:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93138, encodeId=0eb0931388f, content=或者有意义,学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri Jul 15 12:48:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91540, encodeId=69a391540bd, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91541, encodeId=086491541ef, content=研究很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=)]
    2016-08-20 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656708, encodeId=96ea1656e0876, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Aug 20 16:04:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995745, encodeId=31561995e450d, content=<a href='/topic/show?id=edd21655a4' target=_blank style='color:#2F92EE;'>#AAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1655, encryptionId=edd21655a4, topicName=AAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Dec 14 08:04:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938602, encodeId=5da719386024d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jul 30 06:04:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93138, encodeId=0eb0931388f, content=或者有意义,学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri Jul 15 12:48:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91540, encodeId=69a391540bd, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91541, encodeId=086491541ef, content=研究很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=)]
    2016-12-14 ay2000fy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656708, encodeId=96ea1656e0876, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Aug 20 16:04:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995745, encodeId=31561995e450d, content=<a href='/topic/show?id=edd21655a4' target=_blank style='color:#2F92EE;'>#AAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1655, encryptionId=edd21655a4, topicName=AAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Dec 14 08:04:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938602, encodeId=5da719386024d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jul 30 06:04:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93138, encodeId=0eb0931388f, content=或者有意义,学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri Jul 15 12:48:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91540, encodeId=69a391540bd, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91541, encodeId=086491541ef, content=研究很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=)]
    2016-07-30 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656708, encodeId=96ea1656e0876, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Aug 20 16:04:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995745, encodeId=31561995e450d, content=<a href='/topic/show?id=edd21655a4' target=_blank style='color:#2F92EE;'>#AAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1655, encryptionId=edd21655a4, topicName=AAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Dec 14 08:04:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938602, encodeId=5da719386024d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jul 30 06:04:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93138, encodeId=0eb0931388f, content=或者有意义,学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri Jul 15 12:48:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91540, encodeId=69a391540bd, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91541, encodeId=086491541ef, content=研究很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=)]
    2016-07-15 午夜星河

    或者有意义,学习中

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1656708, encodeId=96ea1656e0876, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Aug 20 16:04:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995745, encodeId=31561995e450d, content=<a href='/topic/show?id=edd21655a4' target=_blank style='color:#2F92EE;'>#AAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1655, encryptionId=edd21655a4, topicName=AAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Dec 14 08:04:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938602, encodeId=5da719386024d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jul 30 06:04:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93138, encodeId=0eb0931388f, content=或者有意义,学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri Jul 15 12:48:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91540, encodeId=69a391540bd, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91541, encodeId=086491541ef, content=研究很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=)]
    2016-06-29 milkshark

    值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1656708, encodeId=96ea1656e0876, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sat Aug 20 16:04:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995745, encodeId=31561995e450d, content=<a href='/topic/show?id=edd21655a4' target=_blank style='color:#2F92EE;'>#AAA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1655, encryptionId=edd21655a4, topicName=AAA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f34c147, createdName=ay2000fy, createdTime=Wed Dec 14 08:04:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938602, encodeId=5da719386024d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jul 30 06:04:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93138, encodeId=0eb0931388f, content=或者有意义,学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Fri Jul 15 12:48:00 CST 2016, time=2016-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91540, encodeId=69a391540bd, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=91541, encodeId=086491541ef, content=研究很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Wed Jun 29 09:18:00 CST 2016, time=2016-06-29, status=1, ipAttribution=)]
    2016-06-29 milkshark

    研究很好

    0

相关资讯

Neurology:早期治疗动脉瘤可减少aSAH患者住院死亡率

荷兰乌得勒支大学医学院Rudolf Magnus脑中心神经外科Mervyn D I Vergouwen和同事研究动脉瘤性蛛网膜下腔出血后死亡原因的时间变化趋势。研究结果2015年11月20日在Neurology在线发表。早期动脉瘤治疗可减少aSAH住院患者再出血死亡例数,减少住院死亡率。研究结果强调早期闭塞动脉瘤和其他治疗策略减少再出血风险,提高aSAH患者预后的必要性。

NEJM:大隐静脉移植后出现动脉瘤——病例报道

女性患者,78岁,因呼吸短促和疲劳就诊于急诊科。30年前曾接受冠状动脉旁路移植术治疗,存在54包年的吸烟史。

Stroke:颅内动脉瘤≥5毫米显著增加破裂风险!

未破裂颅内动脉瘤的自然史尚不清楚,管理战略也并不明确。从2003年1月至2012年12月,研究人员招募了动脉瘤患者参加此次试验。总体而言,共有2252例患者的2897例动脉瘤有资格被进行分析,1960例符合条件的动脉瘤接受保守治疗。研究人员使用计算机断层摄影术,DSA,或磁共振血管造影进行精确的三维评价。然后评估了与动脉瘤的特征,人口统计,和已知的健康/生活方式风险因素相关的动脉瘤破裂,死亡率及发

Stroke:未破裂动脉瘤的危险因素——瘤体大小

背景;未破裂颅内动脉瘤的自然史尚不清楚,管理策略不明确。方法:从2003年1月到2012年12月,研究者招募在其机构登记的动脉瘤的患者。共有2252例2897个动脉瘤患者有资格进行分析,1960个符合条件的动脉瘤保守治疗。使用CT血管造影,DSA,或磁共振血管造影进行精确的三维评价。然后,研究者评估与动脉瘤的特征,人口学资料,和已知的健康/生活方式等危险因素相关的脉瘤破裂的风险,死亡率和发病率。结

Pipeline密网支架治疗颅内复杂动脉瘤显优势

首都医科大学宣武医院神经外科在国内率先开展Pipeline密网支架治疗颅内复杂动脉瘤效果较好,随访结果显示,使用该技术治疗的患者动脉瘤均完全治愈。颅内动脉瘤人群患病率约为7%,复杂颅内动脉瘤包括直径大于25毫米的巨大动脉瘤,以及特殊部位动脉瘤如海绵窦内、床突段,以及颅内动脉扩张等。既往治疗这些疾病的主要手段包括开颅动脉瘤直接夹闭,动脉瘤孤立加搭桥,及介入治疗等,治疗难度高、手术风险大,术后并发症发

Am J Med:巨大感染性髂内动脉假性动脉瘤——案例报道

53岁男性反复发热、左腰痛进行性加重2个月,在这之前的几个月患者有盗汗、畏寒、疲劳、咽痛、体重下降10KG。既往史和家族史无特殊。查体:生命体征平稳,腹部无压痛。辅助检查:肌酸激酶升高(233 U/L),红细胞沉降率升高(64 mm/hr),C反应蛋白升高(62.3 mg/L)。血培养D族沙门氏菌阳性。CT血管造影提示靠近在左侧髂总动脉的分叉处有一个巨大的孤立的假动脉瘤,大小83 mm × 92